Bayer Finerenone secures USFDA Priority Review designation for heart failure

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-03-17 11:00 GMT   |   Update On 2025-03-17 11:00 GMT

Berlin: Bayer has announced that the Company has received Priority Review designation from the U.S. Food and Drug Administration (FDA) for finerenone for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%, i.e. mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

The regulatory submission was based on the positive results from the Phase III FINEARTS-HF study, detailed results of which were presented at ESC Congress 2024, and simultaneously published in the New England Journal of Medicine.

The FDA grants Priority Review designation for the evaluation of medicines that, if approved, would offer significant improvements in the efficacy or safety of the treatment, diagnosis, or prevention of serious conditions when compared to available therapies. Based on a priority review designation, the FDA’s goal is to take action on a New Drug Application within 6 months of submission, compared to 10 months under standard review. This would result in a PDUFA date and a potential approval of Kerendia in the U.S. in heart failure with an LVEF of ≥40% in the third quarter of 2025.
“The FDA’s Priority Review designation reinforces the potential of finerenone to emerge as a new pillar of therapy, advancing the treatment paradigm in heart failure with a left ventricular ejection fraction (LVEF) of ≥40%,” said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer. “Currently, there are limited treatment options with proven efficacy available to physicians. We are excited about the Priority Review designation for finerenone, as this brings us an important step closer to bringing finerenone to patients as quickly as possible."

Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) and the drug targeting the mineralocorticoid receptor (MR) pathway that has demonstrated cardiovascular benefits in patients with HF and an LVEF of ≥40% in the Phase III study FINEARTS-HF. Finerenone is already marketed as Kerendia or, in some countries, as Firialta, and approved for the treatment of adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in more than 90 countries worldwide, including in China, Europe, Japan, and the U.S.

By targeting MR and renin-angiotensin-aldosterone system (RAAS) overactivation, finerenone addresses key aspects of HF with an LVEF ≥40%, including hemodynamic factors and inflammatory and fibrotic processes. Results from the Phase III study FINEARTS-HF demonstrate that compared to placebo, finerenone showed a statistically significant improvement in cardiovascular outcomes in patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of greater than or equal to 40%.

The supplemental New Drug Application submitted to the U.S. FDA is based on positive data from the FINEARTS-HF study, which is part of the ongoing MOONRAKER study program with finerenone. Finerenone has also been submitted for marketing authorization in HF with an LVEF of ≥40% in China, the EU, and Japan, and these applications are currently under review. Further regulatory applications to health authorities in other markets worldwide will follow.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News